Welcome to our dedicated page for Merrimack Pharma news (Ticker: MACK), a resource for investors and traders seeking the latest updates and insights on Merrimack Pharma stock.
Merrimack Pharmaceuticals (MACK) pioneers precision oncology treatments through its unique integration of systems biology and engineered therapeutics. This dedicated news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Comprehensive Coverage: Track all material announcements including trial phase results, partnership agreements, and financial disclosures. Our curated feed ensures immediate access to FDA submissions, research breakthroughs, and pipeline expansion details critical for informed analysis.
Key Focus Areas: Updates span biomarker validation studies, therapeutic candidate progress, and intellectual property developments. Content maintains rigorous separation between corporate communications and third-party analysis for compliance clarity.
Staying Informed: Bookmark this page for real-time access to MACK's evolving position in biopharmaceutical innovation. Verify time-sensitive data through official SEC filings and clinical trial registries when required.
Merrimack Pharmaceuticals, Inc. announced stockholder approval of a Plan of Dissolution and declared a cash liquidating dividend of $15.10 per share of common stock. The dividend is expected to be paid on or about May 17, 2024. The common stock will trade on NASDAQ until May 17, 2024, delisting on May 20, 2024. CEO Gary Crocker expressed gratitude for shareholder support and the opportunity to return milestone proceeds to shareholders.
Merrimack Pharmaceuticals, Inc. announced a planned liquidating cash dividend of $15.10 per share, contingent on stockholder approval of the Plan of Dissolution at a meeting on May 10, 2024. The dividend is set to be paid around May 17, 2024, with potential for higher or lower distributions depending on future developments. The company also hinted at possible additional distributions based on certain agreements. Stockholders are advised to review the definitive proxy statement for more details.
Merrimack Pharmaceuticals announced its intention to voluntarily delist its common stock on NASDAQ, contingent upon stockholder approval of the Plan of Dissolution. The company plans to issue an initial liquidating cash dividend in the range of $14.92 to $15.15 per share, subject to approval. The record date for stockholders to receive the dividend is May 10, 2024, with the stock to go ex-dividend on May 15, 2024. If the Plan of Dissolution is not approved, regular trading will continue. The company urges investors to review the Proxy Statement filed with the SEC for more information.
Merrimack Pharmaceuticals (NASDAQ: MACK) reported a net loss of
FAQ
What is the current stock price of Merrimack Pharma (MACK)?
What is the market cap of Merrimack Pharma (MACK)?
